Drug Profile

Research programme: IL18 heterodimeric Fc-fusion proteins - Xencor

Alternative Names: IL-18-Fc

Latest Information Update: 07 Jun 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Xencor
Class Antineoplastics; Immunoglobulin Fc fragments; Immunotherapies; Interleukins; Proteins; Recombinant fusion proteins
Mechanism of Action Immunostimulants; Interleukin 18 replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

15 Apr 2022 Pharmacodynamics data from a preclinical trial in Cancer presented at the (full name of conference 113th Annual Meeting of the American Association for Cancer Research (AACR-2022) (Xencor website, April 2022)
08 Apr 2022 Preclinical trials in Cancer in USA
08 Apr 2022 Pharmacodynamics data from a preclinical phase trial in cancer released by Xencor (Parenteral) before April 2022

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com